Gemini Therapeutics, Inc. (GMTX)
$1.35
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | GMTX |
|---|---|
| Price | $1.35 |
| Beta | -0.125 |
| Volume Avg. | 0.02M |
| Market Cap | 58.493M |
| Shares () | - |
| 52 Week Range | 1.35-27.1 |
| 1y Target Est | - |
| DCF Unlevered | GMTX DCF -> | |
|---|---|---|
| DCF Levered | GMTX LDCF -> | |
| ROE | -38.78% | Strong Sell |
| ROA | -40.95% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 1.40% | Neutral |
| P/E | - | |
| P/B | 0.56 | Buy |
Latest GMTX news
About
Download (Excel)Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.